Coinbase Founder’s Longevity Startup Triples in Value

Coinbase Founder’s Longevity Startup Triples in Value



Coinbase Founder’s Longevity Startup Triples in Value
Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year.

Leave a Reply

Your email address will not be published. Required fields are marked *